Patients with positive patch test to formaldehyde can be safely vaccinated with formaldehyde-containing vaccines.
formaldehyde
influenza vaccination
patch test
type IV reaction
Journal
Contact dermatitis
ISSN: 1600-0536
Titre abrégé: Contact Dermatitis
Pays: England
ID NLM: 7604950
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
revised:
14
04
2023
received:
19
01
2023
accepted:
30
04
2023
medline:
10
7
2023
pubmed:
25
5
2023
entrez:
25
5
2023
Statut:
ppublish
Résumé
Prophylactic vaccination against influenza and other epidemic viruses is recommended for citizens above 65 years. Several vaccines may contain traces of formaldehyde and are contra-indicated in patients hypersensitive (in the broadest possible meaning) to formaldehyde. Thorough knowledge on the various subtypes of hypersensitivity is sparse among non-dermatologists and non-allergists, and therefore many patients are prevented from vaccination based on a positive patch test to formaldehyde. The purpose of this retrospective study was to investigate whether patients with positive patch test to formaldehyde subsequently receiving a formaldehyde-containing vaccine and developed a severe adverse reaction. From January 2000 to June 2021, 169 patients (>50 years) had a positive formaldehyde patch test at the Department of Dermatology and Allergy Center, Odense University Hospital and were included into this retrospective study. The electronic medical record was assessed for receipt of a formaldehyde-containing vaccine after patch test and for subsequent contact with the Acute Ward in the Region of Southern Denmark within 14 days after vaccination. Of the 158 patients residing in the Region of Southern Denmark, 130 patients were vaccinated with one or more formaldehyde-containing vaccines of whom 123 received an influenza vaccine. No contacts to the acute wards were identified. Although prospective studies would be beneficial, patients with positive patch test to formaldehyde can be safely vaccinated with formaldehyde-containing vaccines.
Sections du résumé
BACKGROUND
BACKGROUND
Prophylactic vaccination against influenza and other epidemic viruses is recommended for citizens above 65 years. Several vaccines may contain traces of formaldehyde and are contra-indicated in patients hypersensitive (in the broadest possible meaning) to formaldehyde. Thorough knowledge on the various subtypes of hypersensitivity is sparse among non-dermatologists and non-allergists, and therefore many patients are prevented from vaccination based on a positive patch test to formaldehyde. The purpose of this retrospective study was to investigate whether patients with positive patch test to formaldehyde subsequently receiving a formaldehyde-containing vaccine and developed a severe adverse reaction.
METHODS/MATERIALS
METHODS
From January 2000 to June 2021, 169 patients (>50 years) had a positive formaldehyde patch test at the Department of Dermatology and Allergy Center, Odense University Hospital and were included into this retrospective study. The electronic medical record was assessed for receipt of a formaldehyde-containing vaccine after patch test and for subsequent contact with the Acute Ward in the Region of Southern Denmark within 14 days after vaccination.
RESULTS
RESULTS
Of the 158 patients residing in the Region of Southern Denmark, 130 patients were vaccinated with one or more formaldehyde-containing vaccines of whom 123 received an influenza vaccine. No contacts to the acute wards were identified.
DISCUSSION
CONCLUSIONS
Although prospective studies would be beneficial, patients with positive patch test to formaldehyde can be safely vaccinated with formaldehyde-containing vaccines.
Substances chimiques
Formaldehyde
1HG84L3525
Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
107-110Informations de copyright
© 2023 The Authors. Contact Dermatitis published by John Wiley & Sons Ltd.
Références
Goossens A, Aerts O. Contact allergy to and allergic contact dermatitis from formaldehyde and formaldehyde releasers. A clinical review and update. Contact Dermatitis. 2022;87(1):20-27.
Ring J. Exacerbation of eczema by formaldehyde-containing Hepatitis B vaccine in formaldehyde-allergic patient. Lancet. 1986;30:522-523.
Kuritzkyl AL, Pratt M. Systemic allergic contact dermatitis after formaldehyde-containing influenza vaccination. J Cutan Med Surg. 2015;19(5):504-506.
Andersen KE, Hjorth N, Menné T. The baboon syndrome: systemically-induced allergic contact dermatitis. Contact Dermatitis. 1984;10(2):97-100.
Nilsson L, Brockow K, Alm J, et al. Vaccination and allergy: EAACI position paper, practical aspects. Pediatr Allergy Immunol. 2017;28:628-640.
Leventhal JS, Berger EM, Brauer JA, Cohen DE. Hypersensitivity reactions to vaccine constituents: a case series and review of literature. Dermatitis. 2012;23(3):102-109.
Aquino MR, Bingemann TA, Nanda A, Maples KM. Delayed allergic skin reactions to vaccines. Allergy Asthma Proc. 2022;43(1):20-29.
Offit PA, Jew RK. Addressing parents' concerns: do vaccines contain harmful preservatives, adjuvants, additives, or residuals? Pediatrics. 2003;112(6):1394-1401.
Johansen JD, Aalto-Korte K, Agner T. European Society of Contact Dermatitis guideline for diagnostic patch testing - recommendations on best practice. Contact Dermatitis. 2015;73(4):195-221.
Lazarov A, David M, Abrahan D, Trattner A. Comparison of reactivity to allergens using the TRUE Test and IQ chamber system. Contact Dermatitis. 2007;56:140-145.